Friday 6 November 2026 Export ASND’s income statement to Excel — free account

Ascendis Pharma A/S

Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.

Revenue: +119.9%
EPS: +612.3%
Free cash flow: +2,335.9%
Total debt: −41.8%

Quarter to June 2026, against a year earlier

256.42 2.97 +1.17%

Follow ASND

Alert me

Market cap: $16.6B
P/E: 18.3×
Fwd P/E: 15.4×
Dividend yield: —
F-score: 5/9
Altman Z: 2.02
Beneish M: −2.51
Dividend safety: n/a

Overview

Ascendis Pharma A/S (ASND) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Ascendis Pharma A/S (ASND) trades at a P/B ratio of 9.8×. Over the past ten years it has ranged from 0.0× (March 2026) to 82.7× (September 2023); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ASND/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Ascendis Pharma A/S P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ASND/metrics/pb-ratio">Ascendis Pharma A/S (ASND) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	0.0×	—
FY2024	0.0×	—
FY2023	0.0×	—
FY2022	24.4×	246.13%
FY2021	7.0×	(20.01%)
FY2020	8.8×	(8.92%)
FY2019	9.7×	24.31%
FY2018	7.8×	23.05%
FY2017	6.3×	133.72%
FY2016	2.7×	(16.96%)

Period	P/B ratio	Change
Jun 2026	10.3×	(58.40%)
Mar 2026	24.7×	—
Dec 2025	0.0×	—
Sep 2025	0.0×	—
42 more quarters	Free account

Against its own ten years

Low 0.0× High 82.7×

Ten-year median 6.4×

Current reading's percentile 74

Company	P/B ratio
HALO Halozyme Therapeutics, Inc. compare	n/m
BBIO BridgeBio Pharma, Inc. compare	n/m
BNTX BioNTech SE Sponsored ADR compare	1.1×
JAZZ Jazz Pharmaceuticals PLC compare	3.5×
ALNY Alnylam Pharmaceuticals, Inc. compare	5.8×
EXEL Exelixis, Inc. compare	9.3×
ASND Ascendis Pharma A/S	9.8×
SMMT Summit Therapeutics PLC compare	17.8×
INSM Insmed, Inc. compare	32.6×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Ascendis Pharma A/S (ASND) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on ASND

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on ASND

Stockrow Weekly